Business Context and Reporting Period
This Form 8-K filing by Picard Medical, Inc. (PMI) reports a significant leadership transition. The report date is June 18, 2026, with the effective separation date for the departing CEO also being June 18, 2026. The company is an emerging growth company incorporated in Delaware and trades on the NYSE American.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, there is no data provided regarding revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the compensation for the new Interim CEO.
Material Changes
- Departure of CEO: Patrick NJ Schnegelsberg stepped down as Chief Executive Officer and Board member effective June 18, 2026. The departure was part of a planned transition and not due to any disagreement with the Company.
- Appointment of Interim CEO: Richard Fang, Ph.D., the current Chairman of the Board and former CEO (2021-2023), was appointed Interim Chief Executive Officer effective June 18, 2026.
- Compensation: Dr. Fang will receive an annual salary of $400,000 while serving as Interim CEO.
Outlook, Risks, and Management Commentary
Management characterized the transition as planned. Dr. Fang brings over 20 years of medical device industry experience, including a successful exit from his previous venture, Reach Surgical. The Board intends to appoint a permanent successor in the future. No specific risks, contingencies, or unusual items were disclosed in this filing beyond the standard leadership change.
Investor Verification Checklist
- Verify the timeline for the search and appointment of a permanent CEO.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the transition.
- Confirm Dr. Fang's continued role as Chairman of the Board alongside his interim CEO duties.
- Check subsequent filings for any changes in the company's strategic direction under new leadership.